A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 (PD-1 Inhibitor), INCB001158 (Arginase Inhibitor), and the Combination in Japanese Participants With Advanced Solid Tumors
Sponsor: Incyte Biosciences Japan GK
This PHASE1 trial investigates Advanced Solid Tumors and Metastatic Solid Tumors and is currently completed. Incyte Biosciences Japan GK leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — May 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Biosciences Japan GK
For direct contact, visit the study record on ClinicalTrials.gov .